Table 1.

Patient demographic data for the Make-an-IMPACT Histiocytosis cohort (n=84)

Age	Mean	31.0
	Range	1–77
Gender	Male	44
	Female	40
Race	White	58
	Asian	8
	Black/African American	5
	Other/Unknown	13
Ethnicity	Non-Hispanic	74
	Hispanic	7
	Unknown	3
Histology	Langerhans Cell Histiocytosis	32
	Rosai-Dorman Disease	16
	Erdheim-Chester Disease	14
	Other Histiocytosis	22
Primary Site	Lymph/Soft Tissue	22
	Skin	17
	Bone	17
	Brain	10
	Other/Unknown	18
Prior Lines of Therapy	0	32
	1	27
	2	13
	3 or more	12
Treatments Received	Steroids	10
	Cytotoxic Chemotherapy*	31
	Targeted Therapy**	7
	Radiation Therapy	1
	Interferon	3
	No prior systemic therapy	32
Vital Status	AWD	58
	NED	16
	DOD	2
	Unknown	8

^*Cytotoxic Chemotherapy: Vinblastine/Vincristine (16), Cytarabine (6), Methotrexate (5), Clofarabine (2), Cladribine (1), Carboplatin/Etoposide/Ifosfamide (1)

^**Targeted Therapies: Trametinib (2), Cobimetinib (2), Vemurafenib (1), Imatinib (1), Sirolimus (1)